#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=So far , S. griseorubens species has mainly been found in soils and was previously demonstrated as a strong antagonistic species conveying broad antifungal activities .
3-1	15-17	So	_	_	_	_
3-2	18-21	far	_	_	_	_
3-3	22-23	,	_	_	_	_
3-4	24-26	S.	person|animal[5]	new|new[5]	coref|coref|coref|coref	4-15|8-33[52_5]|4-15|8-33[52_5]
3-5	27-39	griseorubens	animal|animal[5]	new|new[5]	coref	4-15[13_0]
3-6	40-47	species	animal[5]	new[5]	_	_
3-7	48-51	has	_	_	_	_
3-8	52-58	mainly	_	_	_	_
3-9	59-63	been	_	_	_	_
3-10	64-69	found	_	_	_	_
3-11	70-72	in	_	_	_	_
3-12	73-78	soils	substance	new	_	_
3-13	79-82	and	_	_	_	_
3-14	83-86	was	_	_	_	_
3-15	87-97	previously	_	_	_	_
3-16	98-110	demonstrated	_	_	_	_
3-17	111-113	as	_	_	_	_
3-18	114-115	a	_	_	_	_
3-19	116-122	strong	_	_	_	_
3-20	123-135	antagonistic	_	_	_	_
3-21	136-143	species	_	_	_	_
3-22	144-153	conveying	_	_	_	_
3-23	154-159	broad	abstract[7]	new[7]	_	_
3-24	160-170	antifungal	abstract[7]	new[7]	_	_
3-25	171-181	activities	abstract[7]	new[7]	_	_
3-26	182-183	.	_	_	_	_

#Text=The present research revealed for the first time the activity of the endophytic actinomycete S. griseorubens MPT42 isolated from the stem of L. cubeba .
4-1	184-187	The	abstract[8]	new[8]	_	_
4-2	188-195	present	abstract[8]	new[8]	_	_
4-3	196-204	research	abstract[8]	new[8]	_	_
4-4	205-213	revealed	_	_	_	_
4-5	214-217	for	_	_	_	_
4-6	218-221	the	time[9]	new[9]	_	_
4-7	222-227	first	time[9]	new[9]	_	_
4-8	228-232	time	time[9]	new[9]	_	_
4-9	233-236	the	abstract[10]	new[10]	coref	5-5[19_10]
4-10	237-245	activity	abstract[10]	new[10]	_	_
4-11	246-248	of	abstract[10]	new[10]	_	_
4-12	249-252	the	abstract[10]|person[11]	new[10]|new[11]	_	_
4-13	253-263	endophytic	abstract[10]|person[11]	new[10]|new[11]	_	_
4-14	264-276	actinomycete	abstract[10]|person[11]	new[10]|new[11]	_	_
4-15	277-279	S.	person|animal[13]|abstract[14]	giv|giv[13]|new[14]	ana|coref|coref|ana|coref|coref|ana|coref|coref	5-1[0_14]|7-27|7-26[36_13]|5-1[0_14]|7-27|7-26[36_13]|5-1[0_14]|7-27|7-26[36_13]
4-16	280-292	griseorubens	animal[13]|abstract[14]	giv[13]|new[14]	_	_
4-17	293-298	MPT42	abstract[14]	new[14]	_	_
4-18	299-307	isolated	_	_	_	_
4-19	308-312	from	_	_	_	_
4-20	313-316	the	place[15]	new[15]	ana	6-1[0_15]
4-21	317-321	stem	place[15]	new[15]	_	_
4-22	322-324	of	place[15]	new[15]	_	_
4-23	325-327	L.	place[15]	new[15]	_	_
4-24	328-334	cubeba	place[15]	new[15]	_	_
4-25	335-336	.	_	_	_	_

#Text=Its CEAE extract exhibited a broad-spectrum antimicrobial activity toward various microbial types including drug-sensitive and multidrug-resistant pathogens .
5-1	337-340	Its	abstract|substance[18]	giv|new[18]	_	_
5-2	341-345	CEAE	substance|substance[18]	new|new[18]	_	_
5-3	346-353	extract	substance[18]	new[18]	_	_
5-4	354-363	exhibited	_	_	_	_
5-5	364-365	a	abstract[19]	giv[19]	coref	12-14[80_19]
5-6	366-380	broad-spectrum	abstract[19]	giv[19]	_	_
5-7	381-394	antimicrobial	abstract[19]	giv[19]	_	_
5-8	395-403	activity	abstract[19]	giv[19]	_	_
5-9	404-410	toward	_	_	_	_
5-10	411-418	various	place[20]	new[20]	_	_
5-11	419-428	microbial	place[20]	new[20]	_	_
5-12	429-434	types	place[20]	new[20]	_	_
5-13	435-444	including	place[20]	new[20]	_	_
5-14	445-459	drug-sensitive	place[20]|abstract[21]	new[20]|new[21]	_	_
5-15	460-463	and	place[20]|abstract[21]	new[20]|new[21]	_	_
5-16	464-483	multidrug-resistant	place[20]|abstract[21]	new[20]|new[21]	_	_
5-17	484-493	pathogens	place[20]|abstract[21]	new[20]|new[21]	_	_
5-18	494-495	.	_	_	_	_

#Text=It showed moderate — strong inhibitory effects with MICs values between 80 – 600 µg/mL on 10 different microbes .
6-1	496-498	It	place	giv	_	_
6-2	499-505	showed	_	_	_	_
6-3	506-514	moderate	_	_	_	_
6-4	515-516	—	_	_	_	_
6-5	517-523	strong	abstract[23]	new[23]	coref	7-6[31_23]
6-6	524-534	inhibitory	abstract[23]	new[23]	_	_
6-7	535-542	effects	abstract[23]	new[23]	_	_
6-8	543-547	with	abstract[23]	new[23]	_	_
6-9	548-552	MICs	abstract[23]|substance|abstract[25]	new[23]|new|new[25]	coref|coref|coref|coref	8-21[48_0]|11-12[71_25]|8-21[48_0]|11-12[71_25]
6-10	553-559	values	abstract[23]|abstract[25]	new[23]|new[25]	_	_
6-11	560-567	between	abstract[23]|abstract[25]	new[23]|new[25]	_	_
6-12	568-570	80	abstract[23]|abstract[25]|quantity[26]	new[23]|new[25]|new[26]	_	_
6-13	571-572	–	abstract[23]|abstract[25]|quantity[26]	new[23]|new[25]|new[26]	_	_
6-14	573-576	600	abstract[23]|abstract[25]|quantity[26]|quantity	new[23]|new[25]|new[26]|new	_	_
6-15	577-582	µg/mL	abstract[23]|abstract[25]|quantity[28]	new[23]|new[25]|new[28]	_	_
6-16	583-585	on	abstract[23]|abstract[25]|quantity[28]	new[23]|new[25]|new[28]	_	_
6-17	586-588	10	abstract[23]|abstract[25]|quantity[28]|animal[29]	new[23]|new[25]|new[28]|new[29]	coref	16-8[0_29]
6-18	589-598	different	abstract[23]|abstract[25]|quantity[28]|animal[29]	new[23]|new[25]|new[28]|new[29]	_	_
6-19	599-607	microbes	abstract[23]|abstract[25]|quantity[28]|animal[29]	new[23]|new[25]|new[28]|new[29]	_	_
6-20	608-609	.	_	_	_	_

#Text=Since many novel antibiotics exhibiting strong effects against multiple-drug resistant bacteria have been isolated from medicinal plant-associated endophytic Streptomyces spp. in the last decades , endophytic S. griseorubens MP42 could be a potential candidate for the production of valuable bioactive substances .
7-1	610-615	Since	_	_	_	_
7-2	616-620	many	substance[30]	new[30]	_	_
7-3	621-626	novel	substance[30]	new[30]	_	_
7-4	627-638	antibiotics	substance[30]	new[30]	_	_
7-5	639-649	exhibiting	_	_	_	_
7-6	650-656	strong	abstract[31]	giv[31]	coref	16-24[111_31]
7-7	657-664	effects	abstract[31]	giv[31]	_	_
7-8	665-672	against	_	_	_	_
7-9	673-686	multiple-drug	animal[32]	new[32]	coref	9-8[55_32]
7-10	687-696	resistant	animal[32]	new[32]	_	_
7-11	697-705	bacteria	animal[32]	new[32]	_	_
7-12	706-710	have	_	_	_	_
7-13	711-715	been	_	_	_	_
7-14	716-724	isolated	_	_	_	_
7-15	725-729	from	_	_	_	_
7-16	730-739	medicinal	_	_	_	_
7-17	740-756	plant-associated	_	_	_	_
7-18	757-767	endophytic	_	_	_	_
7-19	768-780	Streptomyces	abstract	new	_	_
7-20	781-785	spp.	_	_	_	_
7-21	786-788	in	_	_	_	_
7-22	789-792	the	time[34]	new[34]	_	_
7-23	793-797	last	time[34]	new[34]	_	_
7-24	798-805	decades	time[34]	new[34]	_	_
7-25	806-807	,	_	_	_	_
7-26	808-818	endophytic	animal[36]|person[37]	giv[36]|new[37]	coref|coref	7-32[38_37]|7-32[38_37]
7-27	819-821	S.	person|animal[36]|person[37]	giv|giv[36]|new[37]	_	_
7-28	822-834	griseorubens	animal[36]|person[37]	giv[36]|new[37]	_	_
7-29	835-839	MP42	person[37]	new[37]	_	_
7-30	840-845	could	_	_	_	_
7-31	846-848	be	_	_	_	_
7-32	849-850	a	person[38]	giv[38]	_	_
7-33	851-860	potential	person[38]	giv[38]	_	_
7-34	861-870	candidate	person[38]	giv[38]	_	_
7-35	871-874	for	person[38]	giv[38]	_	_
7-36	875-878	the	person[38]|abstract[39]	giv[38]|new[39]	_	_
7-37	879-889	production	person[38]|abstract[39]	giv[38]|new[39]	_	_
7-38	890-892	of	person[38]|abstract[39]	giv[38]|new[39]	_	_
7-39	893-901	valuable	person[38]|abstract[39]|substance[40]	giv[38]|new[39]|new[40]	_	_
7-40	902-911	bioactive	person[38]|abstract[39]|substance[40]	giv[38]|new[39]|new[40]	_	_
7-41	912-922	substances	person[38]|abstract[39]|substance[40]	giv[38]|new[39]|new[40]	_	_
7-42	923-924	.	_	_	_	_

#Text=In agreement with previous reports , the present study demonstrated the potential growth inhibiting effect of L. cubeba EO ( MICs of 0.70 – 5.5 mg/mL ) toward a broad array of microbial species , compared with EOs derived from other medicinal plants .
8-1	925-927	In	_	_	_	_
8-2	928-937	agreement	event[41]	new[41]	_	_
8-3	938-942	with	event[41]	new[41]	_	_
8-4	943-951	previous	event[41]|abstract[42]	new[41]|new[42]	_	_
8-5	952-959	reports	event[41]|abstract[42]	new[41]|new[42]	_	_
8-6	960-961	,	_	_	_	_
8-7	962-965	the	abstract[43]	new[43]	coref	11-1[65_43]
8-8	966-973	present	abstract[43]	new[43]	_	_
8-9	974-979	study	abstract[43]	new[43]	_	_
8-10	980-992	demonstrated	_	_	_	_
8-11	993-996	the	abstract[44]	new[44]	coref	19-17[133_44]
8-12	997-1006	potential	abstract[44]	new[44]	_	_
8-13	1007-1013	growth	abstract[44]	new[44]	_	_
8-14	1014-1024	inhibiting	_	_	_	_
8-15	1025-1031	effect	abstract[45]	new[45]	_	_
8-16	1032-1034	of	abstract[45]	new[45]	_	_
8-17	1035-1037	L.	abstract[45]|person|object[47]	new[45]|new|new[47]	coref|coref|coref|coref	11-5[67_47]|11-41|11-5[67_47]|11-41
8-18	1038-1044	cubeba	abstract[45]|object[47]	new[45]|new[47]	_	_
8-19	1045-1047	EO	abstract[45]|object[47]	new[45]|new[47]	_	_
8-20	1048-1049	(	_	_	_	_
8-21	1050-1054	MICs	substance[48]	giv[48]	_	_
8-22	1055-1057	of	substance[48]	giv[48]	_	_
8-23	1058-1062	0.70	substance[48]|abstract[49]	giv[48]|new[49]	_	_
8-24	1063-1064	–	substance[48]|abstract[49]	giv[48]|new[49]	_	_
8-25	1065-1068	5.5	substance[48]|abstract[49]|quantity[50]	giv[48]|new[49]|new[50]	_	_
8-26	1069-1074	mg/mL	substance[48]|abstract[49]|quantity[50]	giv[48]|new[49]|new[50]	_	_
8-27	1075-1076	)	_	_	_	_
8-28	1077-1083	toward	_	_	_	_
8-29	1084-1085	a	abstract[51]	new[51]	_	_
8-30	1086-1091	broad	abstract[51]	new[51]	_	_
8-31	1092-1097	array	abstract[51]	new[51]	_	_
8-32	1098-1100	of	abstract[51]	new[51]	_	_
8-33	1101-1110	microbial	abstract[51]|animal[52]	new[51]|giv[52]	coref	12-10[78_52]
8-34	1111-1118	species	abstract[51]|animal[52]	new[51]|giv[52]	_	_
8-35	1119-1120	,	_	_	_	_
8-36	1121-1129	compared	_	_	_	_
8-37	1130-1134	with	_	_	_	_
8-38	1135-1138	EOs	object	new	_	_
8-39	1139-1146	derived	_	_	_	_
8-40	1147-1151	from	_	_	_	_
8-41	1152-1157	other	plant[54]	new[54]	_	_
8-42	1158-1167	medicinal	plant[54]	new[54]	_	_
8-43	1168-1174	plants	plant[54]	new[54]	_	_
8-44	1175-1176	.	_	_	_	_

#Text=For instance , Ocimum gratissimum EO inhibited both Gram-positive bacteria ( S. aureus and Bacillus spp. ) at the concentration of 93.7 – 150 mg/mL and Gram-negative bacteria ( E. coli , P. aeruginosa , S .
9-1	1177-1180	For	_	_	_	_
9-2	1181-1189	instance	_	_	_	_
9-3	1190-1191	,	_	_	_	_
9-4	1192-1198	Ocimum	_	_	_	_
9-5	1199-1210	gratissimum	_	_	_	_
9-6	1211-1213	EO	_	_	_	_
9-7	1214-1223	inhibited	_	_	_	_
9-8	1224-1228	both	animal[55]	giv[55]	_	_
9-9	1229-1242	Gram-positive	animal[55]	giv[55]	_	_
9-10	1243-1251	bacteria	animal[55]	giv[55]	_	_
9-11	1252-1253	(	animal[55]	giv[55]	_	_
9-12	1254-1256	S.	animal[55]	giv[55]	_	_
9-13	1257-1263	aureus	animal[55]	giv[55]	_	_
9-14	1264-1267	and	animal[55]	giv[55]	_	_
9-15	1268-1276	Bacillus	animal[55]	giv[55]	_	_
9-16	1277-1281	spp.	animal[55]	giv[55]	_	_
9-17	1282-1283	)	animal[55]	giv[55]	_	_
9-18	1284-1286	at	animal[55]	giv[55]	_	_
9-19	1287-1290	the	animal[55]|abstract[56]	giv[55]|new[56]	_	_
9-20	1291-1304	concentration	animal[55]|abstract[56]	giv[55]|new[56]	_	_
9-21	1305-1307	of	animal[55]|abstract[56]	giv[55]|new[56]	_	_
9-22	1308-1312	93.7	animal[55]|abstract[56]|quantity	giv[55]|new[56]|new	_	_
9-23	1313-1314	–	animal[55]|abstract[56]	giv[55]|new[56]	_	_
9-24	1315-1318	150	animal[55]|abstract[56]|quantity[58]	giv[55]|new[56]|new[58]	_	_
9-25	1319-1324	mg/mL	animal[55]|abstract[56]|quantity[58]	giv[55]|new[56]|new[58]	_	_
9-26	1325-1328	and	animal[55]	giv[55]	_	_
9-27	1329-1342	Gram-negative	animal[55]|abstract	giv[55]|new	_	_
9-28	1343-1351	bacteria	animal[55]	giv[55]	_	_
9-29	1352-1353	(	_	_	_	_
9-30	1354-1356	E.	_	_	_	_
9-31	1357-1361	coli	_	_	_	_
9-32	1362-1363	,	_	_	_	_
9-33	1364-1366	P.	place[60]	new[60]	_	_
9-34	1367-1377	aeruginosa	place[60]	new[60]	_	_
9-35	1378-1379	,	_	_	_	_
9-36	1380-1381	S	person	new	_	_
9-37	1382-1383	.	_	_	_	_

#Text=Typhimurium , Klebsiella pneumoniae , Proteus mirabilis ) at the concentration of 107 – 750 mg/mL .
10-1	1384-1395	Typhimurium	_	_	_	_
10-2	1396-1397	,	_	_	_	_
10-3	1398-1408	Klebsiella	_	_	_	_
10-4	1409-1419	pneumoniae	_	_	_	_
10-5	1420-1421	,	_	_	_	_
10-6	1422-1429	Proteus	_	_	_	_
10-7	1430-1439	mirabilis	_	_	_	_
10-8	1440-1441	)	_	_	_	_
10-9	1442-1444	at	_	_	_	_
10-10	1445-1448	the	quantity[62]	new[62]	_	_
10-11	1449-1462	concentration	quantity[62]	new[62]	_	_
10-12	1463-1465	of	quantity[62]	new[62]	_	_
10-13	1466-1469	107	quantity[62]|quantity	new[62]|new	_	_
10-14	1470-1471	–	quantity[62]	new[62]	_	_
10-15	1472-1475	750	quantity[62]|quantity[64]	new[62]|new[64]	_	_
10-16	1476-1481	mg/mL	quantity[62]|quantity[64]	new[62]|new[64]	_	_
10-17	1482-1483	.	_	_	_	_

#Text=Another study showed that Cinnamomum EO ( Lauraceae family ) possessed low MIC values ranging from 1.2 to 12.5 mg/mL against E. coli , C. jejuni , S. aureus , S. enteritidis , S. Typhimurium , L. innocua , and L. monocytogenes .
11-1	1484-1491	Another	abstract[65]	giv[65]	coref	15-1[97_65]
11-2	1492-1497	study	abstract[65]	giv[65]	_	_
11-3	1498-1504	showed	_	_	_	_
11-4	1505-1509	that	_	_	_	_
11-5	1510-1520	Cinnamomum	plant|object[67]	new|giv[67]	coref|coref	12-7[76_67]|12-7[76_67]
11-6	1521-1523	EO	object[67]	giv[67]	_	_
11-7	1524-1525	(	_	_	_	_
11-8	1526-1535	Lauraceae	animal|person[69]	new|new[69]	_	_
11-9	1536-1542	family	person[69]	new[69]	_	_
11-10	1543-1544	)	_	_	_	_
11-11	1545-1554	possessed	_	_	_	_
11-12	1555-1558	low	abstract[71]	giv[71]	_	_
11-13	1559-1562	MIC	object|abstract[71]	new|giv[71]	coref	13-37[91_0]
11-14	1563-1569	values	abstract[71]	giv[71]	_	_
11-15	1570-1577	ranging	_	_	_	_
11-16	1578-1582	from	_	_	_	_
11-17	1583-1586	1.2	quantity	new	_	_
11-18	1587-1589	to	_	_	_	_
11-19	1590-1594	12.5	quantity[73]	new[73]	_	_
11-20	1595-1600	mg/mL	quantity[73]	new[73]	_	_
11-21	1601-1608	against	quantity[73]	new[73]	_	_
11-22	1609-1611	E.	quantity[73]	new[73]	_	_
11-23	1612-1616	coli	quantity[73]	new[73]	_	_
11-24	1617-1618	,	_	_	_	_
11-25	1619-1621	C.	_	_	_	_
11-26	1622-1628	jejuni	_	_	_	_
11-27	1629-1630	,	_	_	_	_
11-28	1631-1633	S.	_	_	_	_
11-29	1634-1640	aureus	_	_	_	_
11-30	1641-1642	,	_	_	_	_
11-31	1643-1645	S.	_	_	_	_
11-32	1646-1657	enteritidis	_	_	_	_
11-33	1658-1659	,	_	_	_	_
11-34	1660-1662	S.	_	_	_	_
11-35	1663-1674	Typhimurium	_	_	_	_
11-36	1675-1676	,	_	_	_	_
11-37	1677-1679	L.	_	_	_	_
11-38	1680-1687	innocua	_	_	_	_
11-39	1688-1689	,	_	_	_	_
11-40	1690-1693	and	_	_	_	_
11-41	1694-1696	L.	person	giv	_	_
11-42	1697-1710	monocytogenes	_	_	_	_
11-43	1711-1712	.	_	_	_	_

#Text=Thus , different chemical constituents in the EO of medicinal plant species affect their potential antimicrobial activity .
12-1	1713-1717	Thus	_	_	_	_
12-2	1718-1719	,	_	_	_	_
12-3	1720-1729	different	substance[75]	new[75]	_	_
12-4	1730-1738	chemical	substance[75]	new[75]	_	_
12-5	1739-1751	constituents	substance[75]	new[75]	_	_
12-6	1752-1754	in	substance[75]	new[75]	_	_
12-7	1755-1758	the	substance[75]|object[76]	new[75]|giv[76]	coref	13-17[0_76]
12-8	1759-1761	EO	substance[75]|object[76]	new[75]|giv[76]	_	_
12-9	1762-1764	of	substance[75]|object[76]	new[75]|giv[76]	_	_
12-10	1765-1774	medicinal	substance[75]|object[76]|animal[78]	new[75]|giv[76]|giv[78]	ana	12-14[0_78]
12-11	1775-1780	plant	substance[75]|object[76]|place|animal[78]	new[75]|giv[76]|new|giv[78]	_	_
12-12	1781-1788	species	substance[75]|object[76]|animal[78]	new[75]|giv[76]|giv[78]	_	_
12-13	1789-1795	affect	_	_	_	_
12-14	1796-1801	their	animal|abstract[80]	giv|giv[80]	coref|coref	17-8[116_0]|17-8[116_0]
12-15	1802-1811	potential	abstract[80]	giv[80]	_	_
12-16	1812-1825	antimicrobial	abstract[80]	giv[80]	_	_
12-17	1826-1834	activity	abstract[80]	giv[80]	_	_
12-18	1835-1836	.	_	_	_	_

#Text=Using E. coli as a model for exploring the mechanism of action of L. cubeba fruit EO , we demonstrated that EO-treated cells were rapidly killed after 2 h of treatment at the EO concentrations ≥ 2 MIC .
13-1	1837-1842	Using	_	_	_	_
13-2	1843-1845	E.	person	new	_	_
13-3	1846-1850	coli	_	_	_	_
13-4	1851-1853	as	_	_	_	_
13-5	1854-1855	a	_	_	_	_
13-6	1856-1861	model	_	_	_	_
13-7	1862-1865	for	_	_	_	_
13-8	1866-1875	exploring	_	_	_	_
13-9	1876-1879	the	abstract[82]	new[82]	_	_
13-10	1880-1889	mechanism	abstract[82]	new[82]	_	_
13-11	1890-1892	of	abstract[82]	new[82]	_	_
13-12	1893-1899	action	abstract[82]|abstract[83]	new[82]|new[83]	ana	14-1[0_83]
13-13	1900-1902	of	abstract[82]|abstract[83]	new[82]|new[83]	_	_
13-14	1903-1905	L.	abstract[82]|abstract[83]	new[82]|new[83]	_	_
13-15	1906-1912	cubeba	abstract[82]|abstract[83]	new[82]|new[83]	_	_
13-16	1913-1918	fruit	abstract[82]|abstract[83]	new[82]|new[83]	_	_
13-17	1919-1921	EO	abstract[82]|abstract[83]|object	new[82]|new[83]|giv	coref	13-34
13-18	1922-1923	,	_	_	_	_
13-19	1924-1926	we	person	acc	ana	15-1
13-20	1927-1939	demonstrated	_	_	_	_
13-21	1940-1944	that	_	_	_	_
13-22	1945-1955	EO-treated	object[86]	new[86]	coref	14-6[93_86]
13-23	1956-1961	cells	object[86]	new[86]	_	_
13-24	1962-1966	were	_	_	_	_
13-25	1967-1974	rapidly	_	_	_	_
13-26	1975-1981	killed	_	_	_	_
13-27	1982-1987	after	_	_	_	_
13-28	1988-1989	2	time[87]	new[87]	_	_
13-29	1990-1991	h	time[87]	new[87]	_	_
13-30	1992-1994	of	time[87]	new[87]	_	_
13-31	1995-2004	treatment	time[87]|abstract	new[87]|new	coref	19-3[128_0]
13-32	2005-2007	at	_	_	_	_
13-33	2008-2011	the	animal[90]	new[90]	_	_
13-34	2012-2014	EO	substance|animal[90]	giv|new[90]	coref	15-21[103_0]
13-35	2015-2029	concentrations	animal[90]	new[90]	_	_
13-36	2030-2031	≥	animal[90]	new[90]	_	_
13-37	2032-2033	2	animal[90]|object[91]	new[90]|giv[91]	_	_
13-38	2034-2037	MIC	animal[90]|object[91]	new[90]|giv[91]	_	_
13-39	2038-2039	.	_	_	_	_

#Text=It is worth noting that the cells showed extraordinary deformation and elongation .
14-1	2040-2042	It	abstract	giv	_	_
14-2	2043-2045	is	_	_	_	_
14-3	2046-2051	worth	_	_	_	_
14-4	2052-2058	noting	_	_	_	_
14-5	2059-2063	that	_	_	_	_
14-6	2064-2067	the	object[93]	giv[93]	_	_
14-7	2068-2073	cells	object[93]	giv[93]	_	_
14-8	2074-2080	showed	_	_	_	_
14-9	2081-2094	extraordinary	abstract[94]	new[94]	_	_
14-10	2095-2106	deformation	abstract[94]	new[94]	_	_
14-11	2107-2110	and	_	_	_	_
14-12	2111-2121	elongation	event	new	_	_
14-13	2122-2123	.	_	_	_	_

#Text=Our study found citral , carveol , and limonene as the main constituents , accounting together for 86.1 % of total L. cubeba fruit EO , concordant with previous studies .
15-1	2124-2127	Our	person|abstract[97]	giv|giv[97]	coref|coref	16-16[109_97]|16-16[109_97]
15-2	2128-2133	study	abstract[97]	giv[97]	_	_
15-3	2134-2139	found	_	_	_	_
15-4	2140-2146	citral	plant	new	coref	18-4
15-5	2147-2148	,	_	_	_	_
15-6	2149-2156	carveol	substance	new	coref	18-6
15-7	2157-2158	,	_	_	_	_
15-8	2159-2162	and	_	_	_	_
15-9	2163-2171	limonene	substance	new	coref	18-9
15-10	2172-2174	as	_	_	_	_
15-11	2175-2178	the	_	_	_	_
15-12	2179-2183	main	_	_	_	_
15-13	2184-2196	constituents	_	_	_	_
15-14	2197-2198	,	_	_	_	_
15-15	2199-2209	accounting	_	_	_	_
15-16	2210-2218	together	_	_	_	_
15-17	2219-2222	for	_	_	_	_
15-18	2223-2227	86.1	quantity[101]	new[101]	_	_
15-19	2228-2229	%	quantity[101]	new[101]	_	_
15-20	2230-2232	of	quantity[101]	new[101]	_	_
15-21	2233-2238	total	quantity[101]|object[103]	new[101]|giv[103]	coref	16-30[112_103]
15-22	2239-2241	L.	quantity[101]|object[103]	new[101]|giv[103]	_	_
15-23	2242-2248	cubeba	quantity[101]|object[103]	new[101]|giv[103]	_	_
15-24	2249-2254	fruit	quantity[101]|substance|object[103]	new[101]|new|giv[103]	_	_
15-25	2255-2257	EO	quantity[101]|object[103]	new[101]|giv[103]	_	_
15-26	2258-2259	,	_	_	_	_
15-27	2260-2270	concordant	_	_	_	_
15-28	2271-2275	with	_	_	_	_
15-29	2276-2284	previous	event[104]	new[104]	coref	16-13[108_104]
15-30	2285-2292	studies	event[104]	new[104]	_	_
15-31	2293-2294	.	_	_	_	_

#Text=Since the effect of each substance on microbes was examined separately in these studies , therefore , the present study aimed at investigating the antimicrobial inhibitory effects possessed by the total EO .
16-1	2295-2300	Since	_	_	_	_
16-2	2301-2304	the	abstract[105]	new[105]	_	_
16-3	2305-2311	effect	abstract[105]	new[105]	_	_
16-4	2312-2314	of	abstract[105]	new[105]	_	_
16-5	2315-2319	each	abstract[105]|substance[106]	new[105]|new[106]	_	_
16-6	2320-2329	substance	abstract[105]|substance[106]	new[105]|new[106]	_	_
16-7	2330-2332	on	abstract[105]|substance[106]	new[105]|new[106]	_	_
16-8	2333-2341	microbes	abstract[105]|substance[106]|animal	new[105]|new[106]|giv	_	_
16-9	2342-2345	was	_	_	_	_
16-10	2346-2354	examined	_	_	_	_
16-11	2355-2365	separately	_	_	_	_
16-12	2366-2368	in	_	_	_	_
16-13	2369-2374	these	event[108]	giv[108]	_	_
16-14	2375-2382	studies	event[108]	giv[108]	_	_
16-15	2383-2384	,	_	_	_	_
16-16	2385-2394	therefore	abstract[109]	giv[109]	_	_
16-17	2395-2396	,	abstract[109]	giv[109]	_	_
16-18	2397-2400	the	abstract[109]	giv[109]	_	_
16-19	2401-2408	present	abstract[109]	giv[109]	_	_
16-20	2409-2414	study	abstract[109]	giv[109]	_	_
16-21	2415-2420	aimed	_	_	_	_
16-22	2421-2423	at	_	_	_	_
16-23	2424-2437	investigating	_	_	_	_
16-24	2438-2441	the	abstract[111]	giv[111]	coref	17-4[115_111]
16-25	2442-2455	antimicrobial	abstract[111]	giv[111]	_	_
16-26	2456-2466	inhibitory	abstract|abstract[111]	new|giv[111]	coref	17-5
16-27	2467-2474	effects	abstract[111]	giv[111]	_	_
16-28	2475-2484	possessed	_	_	_	_
16-29	2485-2487	by	_	_	_	_
16-30	2488-2491	the	object[112]	giv[112]	coref	19-4[0_112]
16-31	2492-2497	total	object[112]	giv[112]	_	_
16-32	2498-2500	EO	object[112]	giv[112]	_	_
16-33	2501-2502	.	_	_	_	_

#Text=This combination showed broad-spectrum inhibitory effects against various microbial species tested .
17-1	2503-2507	This	abstract[113]	new[113]	_	_
17-2	2508-2519	combination	abstract[113]	new[113]	_	_
17-3	2520-2526	showed	_	_	_	_
17-4	2527-2541	broad-spectrum	abstract[115]	giv[115]	_	_
17-5	2542-2552	inhibitory	abstract|abstract[115]	giv|giv[115]	_	_
17-6	2553-2560	effects	abstract[115]	giv[115]	_	_
17-7	2561-2568	against	abstract[115]	giv[115]	_	_
17-8	2569-2576	various	abstract[115]|animal[116]	giv[115]|giv[116]	_	_
17-9	2577-2586	microbial	abstract[115]|animal[116]	giv[115]|giv[116]	_	_
17-10	2587-2594	species	abstract[115]|animal[116]	giv[115]|giv[116]	_	_
17-11	2595-2601	tested	_	_	_	_
17-12	2602-2603	.	_	_	_	_

#Text=In fact , citral , carveol , and limonene are phenolic substances with polarity characteristics that might act on the bacterial cell membrane , inactivate cell adhesions , and/or interact with the outer and inner membrane proteins .
18-1	2604-2606	In	_	_	_	_
18-2	2607-2611	fact	_	_	_	_
18-3	2612-2613	,	_	_	_	_
18-4	2614-2620	citral	plant	giv	_	_
18-5	2621-2622	,	_	_	_	_
18-6	2623-2630	carveol	substance	giv	_	_
18-7	2631-2632	,	_	_	_	_
18-8	2633-2636	and	_	_	_	_
18-9	2637-2645	limonene	substance	giv	coref	18-11[120_0]
18-10	2646-2649	are	_	_	_	_
18-11	2650-2658	phenolic	substance[120]	giv[120]	_	_
18-12	2659-2669	substances	substance[120]	giv[120]	_	_
18-13	2670-2674	with	substance[120]	giv[120]	_	_
18-14	2675-2683	polarity	substance[120]|abstract[121]	giv[120]|new[121]	_	_
18-15	2684-2699	characteristics	substance[120]|abstract[121]	giv[120]|new[121]	_	_
18-16	2700-2704	that	_	_	_	_
18-17	2705-2710	might	_	_	_	_
18-18	2711-2714	act	_	_	_	_
18-19	2715-2717	on	_	_	_	_
18-20	2718-2721	the	place[122]	new[122]	coref	18-36[0_122]
18-21	2722-2731	bacterial	place[122]	new[122]	_	_
18-22	2732-2736	cell	place[122]	new[122]	_	_
18-23	2737-2745	membrane	place[122]	new[122]	_	_
18-24	2746-2747	,	_	_	_	_
18-25	2748-2758	inactivate	_	_	_	_
18-26	2759-2763	cell	place|abstract[124]	new|new[124]	coref|coref	19-12|19-12
18-27	2764-2773	adhesions	abstract[124]	new[124]	_	_
18-28	2774-2775	,	_	_	_	_
18-29	2776-2782	and/or	_	_	_	_
18-30	2783-2791	interact	_	_	_	_
18-31	2792-2796	with	_	_	_	_
18-32	2797-2800	the	substance[126]	new[126]	_	_
18-33	2801-2806	outer	substance[126]	new[126]	_	_
18-34	2807-2810	and	substance[126]	new[126]	_	_
18-35	2811-2816	inner	substance[126]	new[126]	_	_
18-36	2817-2825	membrane	place|substance[126]	giv|new[126]	_	_
18-37	2826-2834	proteins	substance[126]	new[126]	_	_
18-38	2835-2836	.	_	_	_	_

#Text=Consequently , the EO treatment might result in the weakening of cell structure and inhibition of cell growth by creating holes on the cell wall and increasing the cell permeability .
19-1	2837-2849	Consequently	_	_	_	_
19-2	2850-2851	,	_	_	_	_
19-3	2852-2855	the	abstract[128]	giv[128]	_	_
19-4	2856-2858	EO	abstract|abstract[128]	giv|giv[128]	_	_
19-5	2859-2868	treatment	abstract[128]	giv[128]	_	_
19-6	2869-2874	might	_	_	_	_
19-7	2875-2881	result	_	_	_	_
19-8	2882-2884	in	_	_	_	_
19-9	2885-2888	the	event[129]	new[129]	_	_
19-10	2889-2898	weakening	event[129]	new[129]	_	_
19-11	2899-2901	of	event[129]	new[129]	_	_
19-12	2902-2906	cell	event[129]|place|abstract[131]	new[129]|giv|new[131]	coref|coref	19-24|19-24
19-13	2907-2916	structure	event[129]|abstract[131]	new[129]|new[131]	_	_
19-14	2917-2920	and	event[129]	new[129]	_	_
19-15	2921-2931	inhibition	event[129]|event[132]	new[129]|new[132]	_	_
19-16	2932-2934	of	event[129]|event[132]	new[129]|new[132]	_	_
19-17	2935-2939	cell	event[129]|event[132]|abstract[133]	new[129]|new[132]|giv[133]	_	_
19-18	2940-2946	growth	event[129]|event[132]|abstract[133]	new[129]|new[132]|giv[133]	_	_
19-19	2947-2949	by	_	_	_	_
19-20	2950-2958	creating	_	_	_	_
19-21	2959-2964	holes	object[134]	new[134]	_	_
19-22	2965-2967	on	object[134]	new[134]	_	_
19-23	2968-2971	the	object[134]|object[136]	new[134]|new[136]	_	_
19-24	2972-2976	cell	object[134]|place|object[136]	new[134]|giv|new[136]	coref	19-29
19-25	2977-2981	wall	object[134]|object[136]	new[134]|new[136]	_	_
19-26	2982-2985	and	_	_	_	_
19-27	2986-2996	increasing	_	_	_	_
19-28	2997-3000	the	abstract[138]	new[138]	_	_
19-29	3001-3005	cell	place|abstract[138]	giv|new[138]	_	_
19-30	3006-3018	permeability	abstract[138]	new[138]	_	_
19-31	3019-3020	.	_	_	_	_
